Australia markets closed

Pliant Therapeutics Inc (9PT.F)

Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
12.80+0.50 (+4.07%)
At close: 03:29PM CEST
Show:
Balance sheet
Cash flow
Annual

Income statement

All numbers in thousands
Breakdown
ttm
31/12/2023
31/12/2022
31/12/2021
31/12/2020
Total revenue
248
1,580
9,685
7,572
41,817
Operating expenses
Research development
135,670
127,797
96,936
77,549
66,193
Selling general and administrative
59,020
57,928
39,949
27,558
17,269
Total operating expenses
194,690
185,725
136,885
105,107
83,462
Operating income or loss
-194,442
-184,145
-127,200
-97,535
-41,645
Interest expense
1,401
1,267
791
0
-
Total other income/expenses net
-
-
-
-
-366
Income before tax
-170,743
-161,336
-123,321
-97,263
-41,533
Income from continuing operations
-170,743
-161,336
-123,321
-97,263
-41,533
Net income
-170,743
-161,336
-123,321
-97,263
-41,533
Net income available to common shareholders
-170,743
-161,336
-123,321
-97,263
-41,533
Basic EPS
-2.78
-2.75
-2.94
-2.71
-1.95
Diluted EPS
-2.78
-2.75
-2.94
-2.71
-1.95
Basic average shares
55,954
58,719
42,016
35,846
21,344
Diluted average shares
55,954
58,719
42,016
35,846
21,344